
**SUPPLEMENTARY FIGURES**

**Supplementary Figure S1.** Safety end points associated with the use of GLP-1 agonists. RRs for gastrointestinal events, pancreatitis, pancreatic cancer, and retinopathy.


**Supplementary Figure S2.** Safety end points associated with the use of SGLT-2 inhibitors. RRs for genital infection, urinary tract infection, amputation, bone fracture, and diabetic ketoacidosis.

**Supplementary Figure S3.** HRs for composite of cardiovascular death, non-fatal MI, or non-fatal stroke stratified by classes of GLP-1 agonists.

**Supplementary Figure S1.** Safety end points associated with the use of GLP-1 agonists. RRs for gastrointestinal events, pancreatitis, pancreatic cancer, and retinopathy.



**Supplementary Figure S2.** Safety end points associated with the use of SGLT-2 inhibitors. RRs for genital infection, urinary tract infection, amputation, bone fracture, and diabetic ketoacidosis.



**Supplementary Figure S3.** HRs for composite of cardiovascular death, non-fatal MI, or non-fatal stroke stratified by classes of GLP-1 agonists.

